drugset
drugset / Trial / NCT02172742

The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin

NCT02172742 ↗

Phase 1 Completed 13 enrolled Bial - Portela C S.A.
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to investigate the effects of multiple-dose administration of BIA 2-093 on the steady-state pharmacokinetics of digoxin in healthy subjects.

Timeline

Start
2002-05
Primary completion
2002-07
Completion
2002-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.25 mg —
Subject Eslicarbazepine acetate Unknown 1200 mg Oral

Indications

epilepsy